Kenvue
KVUE
$17.67
-0.79%
Kenvue Inc. is the world's largest pure-play consumer health company, operating a portfolio of iconic brands including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena across three reporting segments: Self Care, Essential Health, and Skin Health and Beauty. Spun off from Johnson & Johnson's consumer segment in May 2023, the company holds a dominant position in consumer staples with over $15 billion in annual revenue and approximately 22,000 employees, competing in the household and personal products industry. The current investor narrative is dominated by the announced acquisition by Kimberly-Clark, signed in November 2025 and expected to close in the second half of 2026, which has effectively capped the stock's trading range as arbitrage dynamics replace fundamental price discovery. Recent headlines highlight integration risks and near-term volatility as the deal nears completion, while lingering product litigation and post-IPO underperformance remain overhangs that keep analyst sentiment firmly in neutral territory.…
KVUE
Kenvue
$17.67
Related headlines
Investment Opinion: Should I buy KVUE Today?
The synthesized recommendation is Hold. The core thesis is that KVUE offers a defined merger arbitrage opportunity with 9.5% upside to the analyst average target of $19.50, but this is offset by deteriorating analyst sentiment, an unsustainable dividend payout ratio of 107.55%, and severe relative underperformance versus the market. The consensus recommendation mean of 2.79 (Hold) and the narrow target range of $18.00 to $23.00 reflect a lack of conviction, making a neutral stance appropriate until deal clarity improves.
Supporting evidence for the Hold rating includes: 1) the forward PE of 14.37x is below the trailing PE of 22.32x, implying expected earnings growth, but the estimated EPS average of $1.427 requires a dramatic increase from trailing EPS of $0.0446, which is questionable given 4.49% revenue growth; 2) the PS ratio of 2.18x and EV/EBITDA of 13.77x are reasonable for a consumer staples company but not deeply discounted; 3) profitability is improving with net margin at 12.13% and operating margin at 21.87% in Q1 2026, yet the dividend payout exceeds earnings; 4) free cash flow of $1.823 billion covers the dividend but leaves limited room for error. The implied upside to the average target is 9.5%, which is modest for the risks involved.
The biggest risks that could invalidate the thesis are: 1) deal failure or renegotiation, which could send the stock to the 52-week low of $14.02 (-21%); 2) a dividend cut if earnings decline, which would remove the 4.80% yield support; and 3) continued market share losses in key categories. The rating would upgrade to Buy if the stock pulls back to the $15-$16 range (implying a 5-6% yield and a more attractive arbitrage spread) or if deal terms are improved. It would downgrade to Sell if the merger is blocked or if revenue growth turns negative. Relative to its history, KVUE is undervalued on a PE basis (22.32x vs. 35.26x at IPO), but fairly valued given its low growth profile and merger overhang.
Sign up to view all
KVUE 12-Month Price Forecast
KVUE presents a classic merger-arbitrage situation where the stock's trajectory is tied to the Kimberly-Clark acquisition rather than standalone fundamentals. The 9.5% upside to the average target of $19.50 is modest but relatively low-risk if the deal closes, supported by a 4.80% dividend yield and a beta of 0.426 that limits downside. However, the 107.55% payout ratio and 4.49% revenue growth highlight underlying weaknesses that could pressure the stock if the deal fails. The neutral stance reflects the balanced risk/reward: limited upside from arbitrage but also limited downside due to the deal floor and defensive characteristics. I would upgrade to bullish if the stock pulls back below $16 (improving the arbitrage spread to over 20%) or if deal terms are improved. I would downgrade to bearish if regulatory hurdles emerge or if Q3 2026 earnings show margin deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.50 and implied upside of +10.4% versus the current price.
Average Target
$19.50
0 analysts
Implied Upside
+10.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Kenvue is covered by 12 analysts with a consensus recommendation of "hold" and a recommendation mean of 2.79 on a scale where 1 is Strong Buy and 5 is Strong Sell, indicating a firmly neutral stance. The average target price of $19.50 implies approximately 9.5% upside from the current price of $17.81, a modest return that reflects the limited re-rating potential given the pending acquisition. The consensus leans neutral rather than bullish, with the institutional ratings history showing a pattern of maintained Neutral/Equal Weight/Hold ratings from Citigroup, Barclays, and UBS throughout 2026, and notable downgrades from Jefferies (Buy to Hold in January 2026) and Canaccord Genuity (Buy to Hold in October 2025), suggesting a deteriorating sentiment trend.
The target price range spans from a low of $18.00 to a high of $23.00, a spread of $5.00 or approximately 28% of the current price, which signals moderate uncertainty about the company's trajectory. The high target of $23.00 likely assumes successful integration with Kimberly-Clark, realization of cost synergies, and a re-rating of the combined entity's earnings power, while the low target of $18.00—barely above the current price—prices in deal completion at current terms with minimal upside or potential integration challenges. The estimated EPS range for the forward period is tight at $1.409 to $1.442, indicating high confidence in near-term earnings but limited visibility beyond the deal close. The narrow analyst coverage and the absence of any Strong Buy ratings suggest that institutional interest is muted, which is typical for a company in the midst of a merger and may lead to reduced liquidity and less efficient price discovery once the deal is consummated.
Bulls vs Bears: KVUE Investment Factors
The bear case currently holds stronger evidence due to KVUE's severe relative underperformance (-16.61% vs. SPY over 1 year), deteriorating analyst sentiment with recent downgrades, and a dividend payout ratio exceeding 100%. However, the bull case is anchored by the merger arbitrage opportunity, deep valuation compression from IPO levels, and improving margins. The single most important tension is whether the Kimberly-Clark acquisition closes on current terms or faces delays/ren egotiation due to integration risks or litigation—this binary outcome will dictate whether the stock converges to the $19.50 average target or breaks below the $14.02 floor. With a beta of 0.426 and a 4.80% yield, the stock offers defensive characteristics, but the merger overhang suppresses fundamental price discovery.
Bullish
- Merger Arbitrage Upside to Deal Value: The pending acquisition by Kimberly-Clark, signed November 2025 and expected to close in H2 2026, provides a defined exit path. The analyst average target of $19.50 implies 9.5% upside from $17.81, and the high target of $23.00 suggests 29% upside if deal terms are revised upward or a competing bid emerges.
- Deep Valuation Discount vs. IPO History: The trailing PE has compressed from 35.26x in Q1 2025 to 22.32x currently, while the PS ratio has fallen from 12.27x to 2.18x. This de-rating leaves the stock trading near the low end of its post-IPO valuation range, limiting further multiple compression risk.
- Margin Expansion and Earnings Momentum: Q1 2026 net margin expanded to 12.13% from 8.60% a year earlier, and operating margin jumped to 21.87% from 14.92%, driven by SG&A leverage as expenses fell to $1.453 billion from $1.61 billion. EBITDA margin of 23.28% confirms healthy cash earnings power.
- High Dividend Yield Provides Floor: The 4.80% dividend yield is well above the S&P 500 average and offers a compelling income stream. Trailing twelve-month free cash flow of $1.823 billion comfortably covers the quarterly dividend of approximately $398 million, supporting the payout despite a 107.55% GAAP payout ratio.
Bearish
- Severe Relative Underperformance: KVUE has underperformed SPY by 16.61% over the past year and 5.94% over the past month, with a 1-year price change of -1.60% versus SPY's +15.01%. This persistent weakness reflects investor skepticism about the company's standalone growth prospects and the merger's strategic rationale.
- Anemic Revenue Growth Limits Re-rating: Q1 2026 revenue grew just 4.49% year-over-year to $3.909 billion, consistent with the low-single-digit cadence of the past four quarters. This mature growth profile offers little organic catalyst to drive multiple expansion, especially with the merger capping upside.
- Dividend Payout Exceeds Earnings: The payout ratio of 107.55% means the dividend is not covered by GAAP net income, relying instead on cash flow generation. With a current ratio of 0.958 indicating current liabilities exceed current assets, financial flexibility is constrained, raising questions about dividend sustainability if earnings decline.
- Analyst Sentiment Deteriorating: The consensus recommendation is 'hold' with a mean of 2.79, and recent downgrades from Jefferies (Buy to Hold in January 2026) and Canaccord Genuity (Buy to Hold in October 2025) signal waning confidence. The absence of any Strong Buy ratings and a low target of $18.00—barely above the current price—reflects limited optimism.
KVUE Technical Analysis
Kenvue is in a range-bound consolidation phase with a slight downward bias, evidenced by a 1-year price change of -1.60% and a 6-month gain of just 2.36%. At the current price of $17.81, the stock sits at approximately 31% of its 52-week range of $14.02 to $20.13, positioning it in the lower-middle portion of its annual band. This middling positioning reflects the market's muted enthusiasm: the stock is neither near oversold value territory nor demonstrating breakout momentum, consistent with a merger-arbitrage situation where the price gravitates toward the deal value rather than fundamental fair value. The max drawdown of -34.77% underscores the significant capital destruction suffered since its post-IPO highs, though the recovery from the $14.02 low suggests a floor has been established.
Recent momentum has deteriorated sharply, with a 1-month decline of -6.90% contrasting with the positive 6-month and YTD gains of 2.36% and 2.83%, respectively. This divergence signals a loss of near-term momentum that conflicts with the longer-term stabilization trend, potentially reflecting deal-related uncertainty or broader consumer staples rotation. The 3-month change of -1.71% confirms the recent weakness is not a one-month anomaly, and the relative strength versus SPY of -5.94% over 1 month and -16.61% over 1 year highlights severe underperformance against the broader market. With a short ratio of 3.4, there is a moderate short interest overhang that could amplify volatility around deal milestones or integration news.
Key technical support is anchored at the 52-week low of $14.02, which represents a critical floor approximately 21% below the current price; a breakdown below this level would signal a fundamental reassessment of the Kimberly-Clark deal probability or terms. Resistance is established at the 52-week high of $20.13, roughly 13% above the current price, and a breakout above this level would likely require either a competing bid or a significant upward revision to deal terms. The beta of 0.426 indicates the stock is roughly 57% less volatile than the broader market, which is typical for a consumer staples name but also reflects the dampening effect of the pending acquisition on price swings; this low beta makes the stock suitable for defensive positioning but limits upside participation in market rallies.
Beta
0.43
0.43x market volatility
Max Drawdown
-34.8%
Largest decline past year
52-Week Range
$14-$20
Price range past year
Annual Return
-3.7%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -7.3% | +1.0% |
| 3m | -4.0% | +5.4% |
| 6m | +0.1% | +17.8% |
| 1y | -3.7% | +16.5% |
| ytd | +2.0% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue trajectory shows modest but consistent growth, with the most recent quarter (Q1 2026, ended March 29, 2026) delivering $3.909 billion in revenue, representing 4.49% year-over-year growth versus $3.741 billion in the prior-year quarter. The multi-quarter trend reveals a steady cadence: Q4 2025 revenue was $3.78 billion, Q3 2025 was $3.764 billion, and Q2 2025 was $3.839 billion, indicating stable top-line performance with no dramatic acceleration or deceleration. Segment data shows Self Care as the largest contributor at $1.699 billion, followed by Essential Health at $1.151 billion and Skin Health and Beauty at $1.059 billion; the balanced portfolio provides diversification but also limits the potential for a single high-growth catalyst to transform the investment case. The low-single-digit growth profile is characteristic of mature consumer staples and suggests the company is primarily a cash-flow and dividend story rather than a growth vehicle.
Profitability remains solid and is showing improvement, with Q1 2026 net income of $474 million translating to a net margin of 12.13%, up from 8.60% in Q1 2025 and 8.73% in Q4 2025. The gross margin of 58.89% in the latest quarter is consistent with the 56.53% to 59.14% range seen over the past eight quarters, reflecting stable pricing power and brand equity in the consumer health space. Operating income of $855 million in Q1 2026 represents an operating margin of 21.87%, a significant expansion from 14.92% in the year-ago quarter, driven by SG&A leverage as selling, general and administrative expenses declined to $1.453 billion from $1.61 billion. The EBITDA of $910 million in Q1 2026, with an EBITDA margin of 23.28%, confirms that the company is generating healthy cash earnings despite the modest revenue growth.
The balance sheet presents a mixed picture: the debt-to-equity ratio of 0.79 is moderate for a consumer staples company, but the current ratio of 0.958 indicates that current liabilities slightly exceed current assets, signaling potential short-term liquidity tightness. Free cash flow on a trailing twelve-month basis is $1.823 billion, which comfortably covers the quarterly dividend of approximately $398 million, though the payout ratio of 107.55% on a trailing basis suggests the dividend is not fully covered by GAAP net income and relies on cash flow generation. Return on equity of 13.66% and return on assets of 6.99% are respectable but not exceptional, reflecting the capital-intensive nature of the branded consumer goods business. The company's ability to fund growth internally is adequate, but the high payout ratio and moderate leverage limit financial flexibility, which may be a consideration in the context of the pending Kimberly-Clark acquisition.
Quarterly Revenue
$3.9B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
58.9%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Given that Kenvue is profitable with positive net income of $474 million in the most recent quarter and trailing EPS of $0.0446, the PE ratio is the appropriate primary valuation metric. The trailing PE of 22.32x compares to a forward PE of 14.37x, implying the market expects significant earnings growth over the next twelve months, likely driven by margin expansion and the realization of cost synergies. The wide gap between trailing and forward multiples—a 35.6% compression—suggests that analysts are pricing in a substantial earnings recovery, though the estimated EPS average of $1.427 for the forward period implies a dramatic increase from the current trailing level, which warrants scrutiny given the modest revenue growth trajectory.
On a peer comparison basis, the PS ratio of 2.18x and EV/Sales of 2.72x appear reasonable for a consumer staples company with mid-single-digit growth, though the EV/EBITDA of 13.77x is on the higher end of the range typically seen for mature household and personal products companies. The PB ratio of 3.06x reflects the asset-light nature of the branded consumer goods business but also indicates that the market is paying a premium for intangible brand value. Without explicit industry average multiples in the provided data, the assessment relies on the PEG ratio of 0.524, which suggests the stock is undervalued relative to its growth rate—though this metric is less reliable for low-growth companies where small changes in the growth rate can dramatically alter the ratio.
Historically, Kenvue's valuation has compressed significantly since its IPO: the PE ratio has declined from 35.26x in Q1 2025 to 22.32x currently, and the PS ratio has fallen from 12.27x to 2.18x over the same period. The PB ratio has similarly declined from 4.57x to 3.06x, indicating a sustained de-rating that reflects the market's reassessment of the company's growth prospects and the overhang of the Kimberly-Clark acquisition. The current PE of 22.32x is near the lower end of its historical range since going public, which could signal either a value opportunity or a recognition that the company's growth profile does not justify premium multiples. The dividend yield of 4.80% is notably high and provides a valuation floor, but the payout ratio above 100% raises questions about sustainability absent earnings growth.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. The current ratio of 0.958 indicates that current liabilities slightly exceed current assets, signaling potential short-term liquidity tightness. The dividend payout ratio of 107.55% on a trailing basis means the dividend is not fully covered by GAAP net income, relying on free cash flow of $1.823 billion to fund the approximately $398 million quarterly payout. While free cash flow covers the dividend, any earnings decline or revenue shock could force a dividend cut. Additionally, the debt-to-equity ratio of 0.79 is manageable but limits financial flexibility, especially with the pending acquisition requiring integration investments. Revenue concentration in mature categories like Self Care ($1.699 billion in Q1 2026) and Essential Health ($1.151 billion) offers diversification but lacks high-growth catalysts, leaving the company vulnerable to competitive pressures in oral care and pain management.
Market and competitive risks are significant given the stock's low beta of 0.426, which dampens upside participation in market rallies but also provides downside protection. However, the valuation compression risk is real: the trailing PE of 22.32x is near the low end of its post-IPO range, but the forward PE of 14.37x implies aggressive earnings growth that may not materialize given 4.49% revenue growth. Competitive disruption from private-label brands and digital-native consumer health startups could erode market share, particularly in Skin Health and Beauty ($1.059 billion in Q1 2026). Regulatory headwinds, including potential FTC scrutiny of the Kimberly-Clark deal, could delay or block the acquisition, removing the arbitrage support. Recent news highlights integration risks and near-term volatility, with the Zacks article noting that investors should brace for challenges as the deal nears closing. Sector rotation risk is also pertinent: consumer staples have underperformed the broader market, as evidenced by SPY's 15.01% 1-year gain versus KVUE's -1.60%.
The worst-case scenario involves a combination of deal failure or renegotiation at a lower price, coupled with a dividend cut and earnings miss. If the Kimberly-Clark acquisition collapses due to regulatory hurdles or integration concerns, KVUE could retest its 52-week low of $14.02, representing a 21% decline from the current price of $17.81. The analyst low target of $18.00 offers little downside protection, but in a severe scenario, the stock could fall to $14.02 or lower, implying a loss of 21% to 25%. The max drawdown of -34.77% since IPO illustrates the capital destruction possible if sentiment sours. A breakdown below $14.02 would signal a fundamental reassessment of the company's standalone value, potentially triggering further selling pressure and a re-rating to a lower multiple, such as a forward PE of 10x on $1.43 EPS, which would imply a price near $14.30.
FAQ
The most severe risk is merger failure or renegotiation, which could send the stock to its 52-week low of $14.02, a 21% decline. Second, the dividend payout ratio of 107.55% exceeds GAAP earnings, and with a current ratio of 0.958, a dividend cut is possible if cash flow deteriorates. Third, competitive pressures in mature categories like Self Care ($1.699 billion in Q1 2026 revenue) could erode market share and pricing power. Fourth, product litigation, particularly Tylenol autism claims, represents an unresolved liability that could result in a multi-billion dollar settlement. Finally, the stock's low beta of 0.426 limits upside participation in market rallies, and its 16.61% underperformance versus SPY over the past year reflects persistent investor skepticism.
The 12-month forecast has three scenarios: a base case (55% probability) with a target range of $18.50-$20.00, assuming the merger closes on schedule and the stock converges to the $19.50 average target; a bull case (25% probability) with a target range of $21.00-$23.00, driven by a higher bid or faster synergies; and a bear case (20% probability) with a target range of $14.00-$16.00, if the deal fails or litigation worsens. The most likely scenario is the base case, hinging on regulatory approval and deal closure in H2 2026. Key assumptions include stable 4-5% revenue growth and operating margins above 20%. The wide target range reflects uncertainty around the merger outcome.
KVUE trades at a trailing PE of 22.32x and a forward PE of 14.37x, with a PS ratio of 2.18x and EV/EBITDA of 13.77x. Relative to its own history, the stock is undervalued—the PE has compressed from 35.26x at IPO to 22.32x, and the PS ratio has fallen from 12.27x to 2.18x. However, relative to peers in consumer staples, the valuation is fair, reflecting low-single-digit growth and merger uncertainty. The forward PE of 14.37x implies the market expects significant earnings growth, but the estimated EPS of $1.427 requires a dramatic increase from trailing EPS of $0.0446, which may be optimistic. The 4.80% dividend yield provides a valuation floor, but the 107.55% payout ratio suggests the market is pricing in limited dividend growth.
KVUE is a Hold-rated stock with a consensus recommendation mean of 2.79 from 12 analysts. The average target price of $19.50 implies 9.5% upside from the current $17.81, which is modest but supported by a 4.80% dividend yield. The primary risk is the pending Kimberly-Clark acquisition, which could fail or be renegotiated, potentially sending the stock to its 52-week low of $14.02 (-21%). For income-focused investors comfortable with merger risk, it may be a suitable defensive holding, but growth-oriented investors should look elsewhere given 4.49% revenue growth. A pullback below $16 would improve the risk/reward profile and could make it a more compelling buy.
KVUE is best suited for short-to-medium-term investment (6-18 months) as a merger-arbitrage play, with the deal expected to close in H2 2026. The low beta of 0.426 and 4.80% dividend yield make it appropriate for defensive income investors, but the 107.55% payout ratio and 4.49% revenue growth limit long-term total return potential. For long-term holding, the stock lacks a compelling growth story, and the merger outcome will determine whether it remains a standalone entity. A minimum holding period of 12 months is suggested to capture the arbitrage spread and dividend payments, but investors should reassess if the deal faces delays or if margins deteriorate below 20%.